{"id":49756,"date":"2022-10-18T17:02:08","date_gmt":"2022-10-18T15:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/"},"modified":"2022-10-18T17:02:08","modified_gmt":"2022-10-18T15:02:08","slug":"melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/","title":{"rendered":"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022"},"content":{"rendered":"
\n

PARSIPPANY, N.J.–(BUSINESS WIRE)–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19\u2013 22, 2022, in Washington, D.C. Additionally, new rezafungin clinical and preclinical data will be presented in six poster presentations. As previously announced, Melinta has licensed the U.S. commercial rights to rezafungin, an investigational candidate currently under FDA review, from Cidara Therapeutics.\n<\/p>\n

<\/a><\/p>\n

\nIDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).\n<\/p>\n

\nDetails of the presentations are provided below. The complete program of titles and abstracts can be accessed on the IDWeek 2022 website at www.idweek.org<\/a>.\n<\/p>\n

\nMelinta Portfolio Poster Presentations<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nProduct<\/b>\n<\/p>\n<\/td>\n

\n

\nTitle<\/b>\n<\/p>\n<\/td>\n

\n

\nPoster Number<\/b>\n<\/p>\n<\/td>\n

\n

\nDate<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nMeropenem-Vaborbactam\n<\/p>\n<\/td>\n

\n

\nActivity of Novel \u03b2<\/span> -Lactam\/ \u03b2<\/span> -Lactamase Inhibitor (BL\/BLI) Combinations Against AmpC-Producing Species Collected in United States Hospitals\n<\/p>\n<\/td>\n

\n

\nPoster 124\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nMeropenem-Vaborbactam\n<\/p>\n<\/td>\n

\n

\nFrequency of Carbapenemases in United States Hospitals (2016-2020) and Activity of Meropenem-Vaborbactam and Comparator Agents Tested Against These Isolates\n<\/p>\n<\/td>\n

\n

\nPoster 126\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOritavancin\n<\/p>\n<\/td>\n

\n

\nOritavancin Activity Against Gram-positive Pathogens Causing Bloodstream Infections in Hematology\/Oncology and Transplant Units in US Medical Centers (2010-2019)\n<\/p>\n<\/td>\n

\n

\nPoster 430\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nMeropenem-Vaborbactam\n<\/p>\n<\/td>\n

\n

\nActivity of Meropenem-Vaborbactam and Comparators Against Isolates from Patients in Hematology\/Oncology and Transplant Units in the United States\n<\/p>\n<\/td>\n

\n

\nPoster 644\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nMinocycline for Injection\n<\/p>\n<\/td>\n

\n

\nTrends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus <\/i>Species Complex and Stenotrophomonas maltophilia <\/i>Isolates to Minocycline, 2014-2021\n<\/p>\n<\/td>\n

\n

\nPoster 645\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOritavancin\n<\/p>\n<\/td>\n

\n

\nActivity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci<\/i> Causing Bloodstream Infections in US Medical Centers (2017-2019)\n<\/p>\n<\/td>\n

\n

\nPoster 646\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDelafloxacin\n<\/p>\n<\/td>\n

\n

\nIn Vitro <\/i>Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nPoster 2176\n<\/p>\n<\/td>\n

\n

\nSaturday, October 22, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nMinocycline for Injection\n<\/p>\n<\/td>\n

\n

\nMortality Associated with Stenotrophomonas maltophilia<\/i> Bloodstream Infection In Patients With Leukemia\n<\/p>\n<\/td>\n

\n

\nPoster 1844\n<\/p>\n<\/td>\n

\n

\nSaturday, October 22, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOritavancin\n<\/p>\n<\/td>\n

\n

\nOritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections\n<\/p>\n<\/td>\n

\n

\nPoster 1845\n<\/p>\n<\/td>\n

\n

\nSaturday, October 22, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nRezafungin Poster Presentations<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n
\n

\nProduct<\/b>\n<\/p>\n<\/td>\n

\n

\nTitle<\/b>\n<\/p>\n<\/td>\n

\n

\nPoster Number<\/b>\n<\/p>\n<\/td>\n

\n

\nDate<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRezafungin\n<\/p>\n<\/td>\n

\n

\nOutcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and\/or Invasive Candidiasis\n<\/p>\n<\/td>\n

\n

\nPoster 231\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022; 12:15-1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRezafungin\n<\/p>\n<\/td>\n

\n

\nAssessment of The Proportion of Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia Who Received an Echinocandin and Were Potentially Eligible for an Earlier Hospital Discharge\n<\/p>\n<\/td>\n

\n

\nPoster 468\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022, 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRezafungin\n<\/p>\n<\/td>\n

\n

\nHealthcare Resource Utilization among Hospitalized Patients with Candidemia and Invasive Candidiasis without Candidemia Who Received Definitive Treatment with an Echinocandin Across United States (US) Hospitals\u200b\n<\/p>\n<\/td>\n

\n

\nPoster 469\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022, 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRezafungin\n<\/p>\n<\/td>\n

\n

\nImpact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)\n<\/p>\n<\/td>\n

\n

\nPoster 592\n<\/p>\n<\/td>\n

\n

\nThursday, October 20, 2022,\n<\/p>\n

\n12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRezafungin\n<\/p>\n<\/td>\n

\n

\nCoadministration of Rezafungin Does Not Impact the Pharmacokinetics of Cyclosporine, Ibrutinib, Mycophenolate Mofetil, or Venetoclax\n<\/p>\n<\/td>\n

\n

\nPoster 1694\n<\/p>\n<\/td>\n

\n

\nSaturday, October 22, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRezafungin\n<\/p>\n<\/td>\n

\n

\nRezafungin Activity against Candida<\/i> spp. and Aspergillus<\/i> spp. Isolates Causing Invasive Infections Worldwide in 2021\n<\/p>\n<\/td>\n

\n

\nPoster 1731\n<\/p>\n<\/td>\n

\n

\nSaturday, October 22, 2022; 12:15 \u2013 1:30 PM\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Melinta Therapeutics<\/b>\n<\/p>\n

\nMelinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes six commercial-stage products: Baxdela\u00ae (delafloxacin), Kimyrsa\u00ae (oritavancin), Minocin\u00ae (minocycline) for Injection, Orbactiv\u00ae (oritavancin), TOPROL-XL\u00ae (metoprolol succinate) and Vabomere\u00ae (meropenem and vaborbactam). Melinta also has a licensing agreement in place with Cidara Therapeutics securing the rights to market and distribute development candidate rezafungin in the United States.\n<\/p>\n

\nWith an unsurpassed commitment to providers and the patients they serve, Melinta works to ensure that all people who need their therapies can receive them. Melinta focuses its expanding portfolio on serving patients with an unmet need to make the most meaningful impact. Melinta is dedicated to innovation while staying grounded in what matters most: patients. For additional information regarding Melinta\u2019s products, including product indication and important safety information, please visit our website at https:\/\/melinta.com<\/a>.\n<\/p>\n

\nFor additional information regarding Cidara Therapeutics and rezafungin, please visit https:\/\/www.cidara.com\/<\/a>.\n<\/p>\n

\nTOPROL-XL\u00ae is a registered trademark of AstraZeneca Pharmaceuticals LP and is used with permission.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSusan Blum
\n
Chief Financial Officer
\n
Melinta Therapeutics, LLC
\n
908-617-1300
\n
info@melinta.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PARSIPPANY, N.J.–(BUSINESS WIRE)–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19\u2013 22, 2022, in Washington, D.C. Additionally, new rezafungin clinical and preclinical data will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49756","6":"format-standard","7":"category-industry"},"yoast_head":"\nMelinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PARSIPPANY, N.J.–(BUSINESS WIRE)–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19\u2013 22, 2022, in Washington, D.C. Additionally, new rezafungin clinical and preclinical data will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-18T15:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221018005967\/en\/1605839\/21\/image004.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022\",\"datePublished\":\"2022-10-18T15:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/\"},\"wordCount\":728,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005967\\\/en\\\/1605839\\\/21\\\/image004.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/\",\"name\":\"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005967\\\/en\\\/1605839\\\/21\\\/image004.jpg\",\"datePublished\":\"2022-10-18T15:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005967\\\/en\\\/1605839\\\/21\\\/image004.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005967\\\/en\\\/1605839\\\/21\\\/image004.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/","og_locale":"en_US","og_type":"article","og_title":"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 - Pharma Trend","og_description":"PARSIPPANY, N.J.–(BUSINESS WIRE)–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19\u2013 22, 2022, in Washington, D.C. Additionally, new rezafungin clinical and preclinical data will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-18T15:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221018005967\/en\/1605839\/21\/image004.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022","datePublished":"2022-10-18T15:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/"},"wordCount":728,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005967\/en\/1605839\/21\/image004.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/","url":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/","name":"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005967\/en\/1605839\/21\/image004.jpg","datePublished":"2022-10-18T15:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221018005967\/en\/1605839\/21\/image004.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221018005967\/en\/1605839\/21\/image004.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/melinta-therapeutics-announces-presentation-of-new-data-on-infectious-disease-portfolio-at-idweek-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49756"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49756\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}